Table 1:

Baseline Demographics

	AOHD	JOHD	p-value
N	9,524	90	N/A
Age, mean ± S.D.	51.8 ± 12.0	19.4 ± 4.8	<0.001
Males, N (%)	4,645 (48.8)	40 (44.4)	0.477
BMI, mean ± S.D.	25.1 ± 5.0	22.5 ± 4.9	<0.001
CAG, mean ± S.D.	43.6 ± 3.0	67.4 ± 10.7	<0.001
Disease Duration, mean ± S.D.	2.1 ± 2.3	2.9 ± 2.8	0.001
Age of Clinical Dx, mean ± S.D.	49.7 ± 12.0	16.5 ± 4.3	<0.001
Years Followed, mean ± S.D.	2.63 ± 1.59	2.63 ± 1.61	0.991
Disease Burden, mean ± S.D.	390.4 ± 86.7	582.9 ± 119.6	<0.001
TMS, mean ± S.D.	29.7 ± 17.4	40.5 ± 20.5	<0.001
Antipsychotic Use, N (%)	2680 (28.1)	24 (26.7)	0.848
Tetrabenazine Use, N (%)	1142 (12.0)	9 (10.0)	0.677
Levodopa Use, N (%)	363 (3.8)	12 (13.3)	<0.001

AOHD, Adult-Onset HD; CAG, Cytosine-Adenine-Guanine; Dx, Diagnosis; HD, Huntington Disease; JOHD, Juvenile-Onset HD; TMS, Total Motor Score